| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/07/2023 | 316.62% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 02/02/2022 | 524.93% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 01/24/2022 | 941.56% | ThinkEquity | → $10 | Initiates Coverage On | → Buy |
What is the target price for Context Therapeutics (CNTX)?
The latest price target for Context Therapeutics (NASDAQ: CNTX) was reported by HC Wainwright & Co. on February 7, 2023. The analyst firm set a price target for $4.00 expecting CNTX to rise to within 12 months (a possible 316.62% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Context Therapeutics (CNTX)?
The latest analyst rating for Context Therapeutics (NASDAQ: CNTX) was provided by HC Wainwright & Co., and Context Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.
Is the Analyst Rating Context Therapeutics (CNTX) correct?
While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a reiterated with a price target of $0.00 to $4.00. The current price Context Therapeutics (CNTX) is trading at is $0.96, which is within the analyst's predicted range.